Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedicureTSXV:MPH +2.88%57 Buyback Yield % is 0.00 as of Jul. 15, 2026. GuruFocus rates TSXV:MPH with a GF Score™ of 57/100 and a GF Value™ of C$1.56 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 290 Drug Manufacturers companies, Medicure ranks worse than 344827.24% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Medicure's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicure Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicure's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Medicure's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicure (TSXV:MPH) has a Buyback Yield % of 0.00 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Medicure and its competitors. Over the past decade, Medicure's Buyback Yield % has ranged from 1.31 to 272.40. According to the industry distribution chart, Medicure ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Medicure's Buyback Yield % too high?
Medicure's current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 272.40. Based on the distribution chart, Medicure ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicure has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medicure's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicure ranks #999999 out of 290 companies for Buyback Yield %. This places Medicure in the lower half of its industry. Historically, Medicure's own Buyback Yield % has ranged from 1.31 to 272.40 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Medicure and its competitors. Medicure's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicure stock overvalued right now?
Based on GuruFocus' analysis, Medicure (TSXV:MPH) is currently considered Possible Value Trap. The stock's GF Value™ is C$1.56, compared to a current price of C$1.07 — trading 31.4% below its estimated fair value. The current Buyback Yield % is 0.00. Medicure's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Medicure (TSXV:MPH), the current Buyback Yield % is 0.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicure (TSXV:MPH) Overvalued in 2026?
Based on GuruFocus' analysis, Medicure stock appears to be undervalued.
The current stock price of C$1.07 is trading 31.4% below its estimated GF Value™ of C$1.56.
GuruFocus considers Medicure to be Possible Value Trap.
Key valuation signals for TSXV:MPH:
Buyback Yield %: 0.00
GF Value™: C$1.56 vs. price of C$1.07 (31.4% below fair value)
No single metric tells the full story. See the TSXV:MPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
57GF Score
Get the complete analysis for TSXV:MPH
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:MPH has been successfully added to your 
